Frequent allelic deletion at the FHIT locus associated with p53 overexpression in squamous cell carcinoma subtype of Taiwanese non-small-cell lung cancers by Lee, Y-C et al.
Frequent allelic deletion at the FHIT locus associated with p53
overexpression in squamous cell carcinoma subtype of Taiwanese
non-small-cell lung cancers
Y-C Lee
1, C-T Wu
2,5, J-Y Shih
3,5, Y-S Jou
4,5 and Y-L Chang*,2
1Department of Surgery, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei 100, Taiwan;
2Department of
Pathology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei 100, Taiwan;
3Department of Internal
Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei 100, Taiwan;
4Division of Molecular and
Genomic Medicine, National Health Research Institutes, Taipei, Taiwan
The fragile histidine triad (FHIT) gene, encompassing the FRA3B fragile site at chromosome 3p14.2, is a tumour suppressor gene
involved in different tumour types including non-small-cell lung cancers (NSCLCs). In the current study, we examined for allelic
deletion at the FHIT locus in 58 primary and microdissected NSCLCs, for which a clinicopathologic profile was available. We found a
loss of 87.7% in heterozygosity (LOH) frequency at one or more microsatellite markers (D3S1289, D3S2408, D3S1766, D3S1312,
D3S1600). Allelic deletion of D3S1766 was related to tumour histology in 10 of 11 squamous cell carcinomas (90.9%) displaying
LOH compared with nine of 17 adenocarcinomas (52.9%; P¼0.049). Besides, in the subset of adenocarcinomas, a higher rate of
LOH at D3S1289 was observed in male (six out of eight, 75%) than in female patients (four out of 17, 23.5%; P¼0.028). However,
FHIT LOH was not correlated overall with a variety of clinical parameters including sex, smoking status, staging, lymph node
metastasis and survival. These results indicated that the high frequency of FHIT gene disruption was important in the development of
both squamous cell carcinomas and adenocarcinomas. Furthermore, there was no association between LOH at FHIT and protein
expression, suggesting the presence of complex mechanisms of Fhit inactivation. On the other hand, the association between FHIT
LOH and p53 protein overexpression assessment reached statistical significance (P¼0.026), implying that common alterations affect
the two genes in tumour progression.
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Lung cancer is the most common cause of cancer death in Taiwan
(Lee et al, 2002) and in Western countries (Geradts et al, 2000).
With only around 10% of 5-year survival rate, lung cancer caused
more than 6000 deaths per year in Taiwan. The majority of these
tumours are non-small-cell carcinomas (NSCLCs), of which
adenocarcinoma is the most common histological type (Chen
et al, 1990; Ihde and Minna, 1991). Cigarette smoking is the major
risk factor. However, other environmental and genetic factors have
been reported to be associated with the increasing risk of lung
cancer, including HPV 16 of 18 virus infection, water and air
pollution, cooking fume exposure and polymorphisms of cancer
susceptible genes.
Field cancerisation and multistep tumorigenesis are two
concepts that are essential in understanding the underlying
mechanisms of carcinogenesis of the aerodigestive tract. Field
cancerisation was first proposed by Slaughter and Skejkal (1953),
who suggested that a whole tissue field exposed to common
carcinogens, such as cigarette smoke, is at risk for the development
of malignancy due to diffuse injury over time. Multistep
tumorigenesis refers to the multistep process in which genetic
events accumulate and result in malignant transformation (Kinzler
and Vogelstein, 1996).
Recent advances in the molecular genetics of human cancers
have revealed that multiple tumour suppressor genes are involved
in lung carcinogenesis (Yokota and Sugimura, 1993). After the
cloning of the fragile histidine triad (FHIT) gene at 3p14.2 (Ohta
et al, 1996), subsequent genetics studies demonstrated frequent
allelic deletion and aberrant FHIT transcripts were observed in
primary lung cancers (Sozzi et al, 1996; Fong et al, 1997) and cell
lines of small-cell and non-small-cell types (Yanagisawa et al,
1996). The evidence that FHIT suppresses tumorigenicity in cancer
cells (Siprashvili et al, 1997) supports the contention that FHIT is a
tumour suppressor gene. This, together with the recent observa-
tion (Sozzi et al, 1997) that there is more FHIT allelic loss in
carcinomas from smokers than from nonsmokers, strengthens the
case for its involvement in the multistage development of lung
cancer.
There are several reports on the correlation between abnorm-
alities of the FHIT gene and clinicopathologic features in lung
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scancers. Loss of heterozygosity (LOH) at the FHIT gene locus in
adenocarcinoma was less frequent than that in squamous cell
carcinoma (Burke et al, 1998). The correlation between LOH at the
FHIT gene locus and the patients’ survival was different in
different studies (Fong et al, 1997; Sozzi et al, 1997, 1998; Burke
et al, 1998; Tomizawa et al, 1998). Loss of heterozygosity at the
FHIT gene locus in smokers has occurred more frequently than
that in nonsmokers (Sozzi et al, 1997; Zienolddiny et al, 2001). It
was also reported that lack of Fhit staining correlates with LOH at
the FHIT 3p14.2 locus, but not at other loci on 3p (Geradts et al,
2000).
The wild-type p53 protein acts as a transcriptional factor in
turning on the expression of a DNA damage programme by
blocking cell cycle progression in the late G1 phase and by
triggering apoptosis in response to stress signals, including DNA
damage, hypoxia and nucleotide deprivation (Prives and Hall,
1999). Abnormalities of p53 expression by immunostaining were
frequently found in lung cancer including 40–70% of SCLCs and
40–60% of NSCLCs. Previous reports, in our study of Taiwanese
NSCLCs, have also indicated that p53 nuclear expression by
immunostaining analysis detected more frequent stainable expres-
sion in squamous cell carcinoma than that in adenocarcinoma
(Chang et al, 2003) In addition, p53 overexpression and the loss of
Fhit expression has been significantly more common in tumours
from smokers than those of nonsmokers (Chang et al, 2003).
Since frequent LOH is a hallmark of genomic instability and
commonly used as a genetic marker for cancer, we aimed to
conduct microsatellite analysis for allelic deletion of FHIT locus
for examining the genetic mechanism of allelic deletion with loss of
Fhit protein expression. The results of allelic deletion were further
characterised for correlation with the clinicopathologic features,
including sex, smoking history, histologic types and differentia-
tion, stage, lymph node metastasis and survival. Furthermore,
immunohistochemical detection of Fhit and p53 proteins was also
compared.
MATERIALS AND METHODS
Lung cancer patients and specimens
In all, 58 lung cancer specimens were obtained from patients who
underwent surgical resection for NSCLC at National Taiwan
University Hospital. These patients were not treated with
neoadjuvant chemotherapy and irradiation therapy. All the speci-
mens were formalin fixed and sectioned for microscopic
examination after applying haematoxylin–eosin stain. Histological
diagnosis and pathological features were obtained including
tumour cell type, direct invasion to surrounding structures and
regional lymph node metastasis. Pathological staging was
performed according to the international staging system for lung
cancer (Mountain, 2002), which is based on tumour size, location
and involvement, and the presence of lymph node metastases.
This study included 23 male and 35 female patients, and the
mean age was 65 years (ranging from 42 to 80 years). The clinical
data of these patients, including sex, age, smoking status, location
of the tumour and ensuing distinct metastases after surgery were
recorded and correlated with the result of Fhit and p53 proteins
expression in each tumour. The four stage IIIB cases included
three multifocal adenocarcinomas within one pulmonary lobe, one
squamous cell carcinoma with pulmonary artery and aortic
invasions. Both of the stage IV cases were multifocal adenocarci-
nomas involving two pulmonary lobes.
Allelotyping by microsatellite markers
Microsatellite analysis was performed in those cases for which
immunohistochemical analysis had been performed. Sections of
the tumour and the adjacent nontumour parts used for
immunohistochemistry were deparaffinised and stained with
haematoxylin–eosin. Tumour cells and adjacent nontumourous
alveolar cells were microdissected from each section. Approxi-
mately 500–1000 cells were dissected from each section. After
microdissection of the tumour tissue, genomic DNA was isolated
from the tumour and normal tissue by proteinase K and extraction
using standard protocols (Burke et al, 1998). Paired tumour and
normal DNA were subjected to polymerase chain reaction (PCR)
analysis. A total of five microsatellite polymorphic markers,
including three dinucleotide (D3S1289, D3S1312 and D3S1600),
one trinucleotide (D3S2408) and one tetranucleotide (D3S1766)
markers that span a total region of about 9 Megabase pairs (Mb) of
FHIT locus on chromosomes 3, were used for allelotyping. The
order of markers and FHIT gene are D3S1289–D3S2408–
D3S1766–FHIT–D3S1312–D3S1600 with physical interval of
1.03, 3.06, 0.66, 1.07, 0.72Mb, respectively, based on the NCBI
released human genome sequence build 34. The average interval of
these markers was approximately 1.8Mb. The microsatellite
markers were purchased from PE Applied Biosystems (Foster
City, CA, USA) and from the set of Multi-Coloured Fluorescent
Human MapPairs Markers (Version 8) of Research Genetics
(Huntsville, AL, USA). These polymorphic microsatellite markers
were labelled with one of the four different fluorescent dyes (FAM,
HEX and TET, NED) on one PCR primer to allow a simultaneous
analysis of many markers based on the differences in fragment
sizes and fluorescent labels. This technique provided a powerful
tool with which to interpret allelic loss on a quantitative basis
efficiently. Polymerase chain reactions were conducted in a volume
of 10ml using 0.03mM of fluorescent-labelled 250mM of each dNTPs,
2m M MgCl2, and 0.5U of FastStart Taq DNA Polymerase (Roche
Molecular System, CA, USA) with protocols provided by the
manufacturers. Polymerase chain reaction products with different
fluorescent labels and fragment sizes were pooled and mixed with
internal fluorescent-labelled (TAMRA) molecular weight markers
for subsequent electrophoresis using a 3700 automated fluorescent
DNA sequencer (PE Applied Biosystems, Foster City, CA, USA).
Allele sizing was determined using the software of GeneScan
Analysis version 3.7 (ABI PRISM) and Genotyper version 3.7 (ABI
PRISM). We used GENOTYPE
TM ROX 50-5000 DNA Ladder as the
fragment calling standards. For each gel image, we employed two
persons for allele sizing of markers independently. For each
marker, the allelic loss ratio was calculated by the formula of (T1/
T2)/(N1/N2), in which T1 and T2 were the values of the two peaks
derived from the tumour and N1 and N2 are from normal tissues.
In the current study, we utilised a more stringent definition for the
occurrence of LOH. First, peak values of both allele areas and allele
heights were used to calculate the allelic loss ration, and thus two
sets of data were generated for each marker. Second, only when
both sets of data were 42- or o0.5-fold, instead of the 1.5-fold
standard commonly used by other studies, the marker region was
considered as an LOH locus (Ko et al, 2002).
Immunohistochemistry
For immunohistochemical demonstration of the Fhit protein
expression in the tumour tissue, 4-mm-thick sections from each
formalin-fixed, paraffin-embedded tissue block were dewaxed with
xylene and rehydrated through a graded series of ethanol.
The sections for IHC of the Fhit protein expression were
autoclaved in 0.01 M phosphate citrate buffer (pH 6.9) at 1211C
for 3min and were treated with 3% H2O2–methanol solution
to reduce endogenous peroxidase activity. These were then
incubated with normal goat serum to reduce nonspecific antibody
binding and were subsequently subjected to the primary antibody
reaction. The antibody for Fhit protein (1:20) (IBL,Gunma,
Japan) was left to react with the sections overnight at 41C.
Detection of the immunoreactive staining was carried out by the
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savidin–biotin–peroxidase complex method according to the
manufacturer’s instructions (Dako Corporation, Carpinteria, CA,
USA). To check for nonspecific staining by the avidin–biotin–
peroxidase complex detection system, the primary antibody was
replaced with BSA. The sections were then subjected to a colour
reaction with 0.05% 3,3-diaminobenzidine in 0.05 M trishy-
drochloride (pH 7.6) containing 0.01% H2O2 and were lightly
counterstained with haematoxylin.
For IHC of the p53 protein expression in the tumour tissue, the
paraffin-embedded tissue block was treated with 0.3% H2O2 in
methanol to block endogenous peroxidase, and heated in a
microwave oven for 20min for antigen retrieval. The tissue
sections were then incubated with normal non-immune goat
serum. After blotting the excessive goat serum, the slides were
incubated with a specific mouse anti-p53 protein antibody ‘p53
(Ab-6), pantropic’ (diluted 1:50) (Oncogene Science, Cambridge,
MA, USA) for 1h at room temperature. After washing with
phosphate-buffered solution (PBS) three times, the sections were
incubated with bionylated goat anti-mouse antibody for 20min at
room temperature. The sections were again washed three times
with PBS, and were then incubated with peroxidase-conjugated
streptavidin for 15min at room temperature. After a third triple
washing with PBS, the sections were then stained with 0.05% (30,3)
diaminobenzidine tetrachloride freshly prepared in 0.05 M Tris-Hcl
(pH 7.6) containing 0.01% H2O2. Finally, the sections were
counterstained with haematoxylin and then mounted.
Immunostaining was classified in the following two groups
according to both intensity and extent: (1) negative, no staining
was present or positive staining was detected in o10% of the cells
and (2) positive immunostaining was present in X10% of the cells.
Two independent pathologists (Y-LC and C-TW) were involved in
the assessment of expression.
Statistical analysis
The correlation between various clinical or pathological para-
meters and the expression of the FHIT gene was analysed using the
Fisher’s exact and log-rank tests. All of the statistical tests were
two-sided.
RESULTS
LOH at the FHIT locus
LOH at the FHIT locus or near the FHIT locus has been found to
be strictly associated with abnormal FHIT transcripts in lung
tumours (Sozzi et al, 1996), therefore loss of one FHIT allele has
been considered a crucial step leading to the loss of function of the
gene. Tumours and matched normal lung tissues were studied
using five microsatellite markers covering a total of 9Mb and the
entire FHIT locus. The normal tissues of all samples were
heterozygous for at least one of these markers. Allelic deletion
was detected in 50 of 57 (87.7%) informative cases at one or more
loci examined when complete data from all five microsatellites
were included (Figure 1).
Correlations of FHIT alterations with clinicopathologic
features and survival
In this cohort of 58 NSCLCs, there was no statistically significant
correlation between LOH at the FHIT locus and clinicopathologic
features of sex, age, smoking history, stage of disease and lymph
node involvement. Likewise, there was no difference in overall
survival between patients with LOH-positive and -negative
tumours at one or more loci (P¼0.208).
LOH at D3S1766 was observed more frequently (10 out of 11;
90.9%) in squamous cell carcinomas than in adenocarcinomas
(nine out of 17; 52.9%; P¼0.049) (Table 1). In addition, allelic loss
affecting D3S1289 was present in six out of eight (75%) of the
adenocarcinomas from male patients, whereas only four out of 17
(23.5%) of the tumours in the female group showed LOH at
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Figure 1 Allelic loss on chromosome 3p14.2 and Fhit and p53 protein
expression in 58 cases of Taiwanese NSCLCs. When analysed by five
microsatellite markers (i.e. D3S1289, D3S2408, D3S1766, D3S1312 and
D3S1600), 50 tumours showed evidence of LOH at one or more sites.
, LOH; , no LOH; , not informative; , not analysed. Fhit and
p53 (þ): X10%, Fhit and p53 ( ): o10%.
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sD3S1289. This difference was statistically significant (P¼0.028)
(Table 1).
Correlations of LOH at the FHIT locus with Fhit protein
expression
Out of 17, 13 (76.5%) tumours with negative Fhit expression
demonstrated LOH at the FHIT locus, whereas six out of 11
(54.5%) tumours with positive Fhit expression demonstrated LOH
at D3S1766 (Table 1). Thus, there was no statistically significant
correlation between LOH at D3S1766 and Fhit expression
(P¼0.409).
Correlations of LOH at the FHIT locus with p53 protein
overexpression
Among 19 cases that showed LOH of FHIT detected by D3S1766, a
synergistic effect of p53 overexpression and LOH at FHIT locus
was observed in all nine cases (100%) in comparision to none in
cases of p53 overexpression and no LOH detected by D3S1766
(P¼0.026) (Table 1). The nine cases with synergistic effect of LOH
at FHIT locus and p53 overexpression were not specifically
associated with any subtype of histology (six squamous cell
carcinomas and three adenocarcinomas) or smoking history
(44%). See supplementary data in Table 1
DISCUSSION
The FHIT gene and its protein product have been the focus of
recent debate with regard to their potential role in tumorigenesis
(Croce et al, 1999). The FHIT gene is fragile in several tumour
types, and FHIT knockout mice models support the idea of a
haploinsufficient mechanism for FHIT-promoting tumour growth
(Zanesi et al, 2001). Therefore, analysis of microsatellite markers is
useful in screening for abnormalities of FHIT in tumour cells. In
the current study, we performed high-density screening of LOH
loci using microsatellite markers to dissect and refine the common
LOH loci located on FHIT gene in NSCLC tissues.
Allelic imbalance at the FHIT and the near FHIT loci was
assessed with the microsatellite markers D3S1289, D3S2408,
D3S1766, D3S1312 and D3S1600. Analysis revealed losses of
heterozygosity in at least one FHIT locus in 86.2% of the cases,
which was more frequent than the results (22–70%) of previous
reports (Sozzi et al, 1996; Fong et al, 1997; Garinis et al, 2001; An
et al, 2002; Petursdottir et al, 2002; Pylkkanen et al, 2002). The
significantly higher incidence of LOH in NSCLCs from our cases
suggest that different somatic or inherited genetic mechanisms
could underlie cancer development in these patients. In addition,
purified genomic DNA isolated from microdissected DNAs could
potentially reduce the masking effects of nontumourous genomic
DNA contaminated in tissue specimens and increased LOH
frequency. Previous studies have shown that the loss of 3p14.2 is
more common in squamous cell carcinomas than in adenocarci-
nomas (Tsuchiya et al, 1992; Testa et al, 1994; Zienolddiny et al,
2001). Our data are consistent with this association (Table 1).
Interestingly, in the subset of 36 informative adenocarcinomas, a
higher LOH rate at D3S1289 was observed in male patients (six out
of eight, 75%) than in female patients (four out of 17, 23.5%;
P¼0.028). The high frequency of deletions found at the FHIT
locus may indicate a possible role for this locus in male patients
with adenocarcinomas.
It has been proposed that the FHIT gene is specifically targeted
by carcinogens in cigarette smoke, and a number of reports
described an increased frequency of FHIT abnormalities at the
DNA or protein level in smokers (Sozzi et al, 1997, 1998; Marchetti
et al, 1998; Nelson et al, 1998; Tomizawa et al, 1998). Our series of
58 NSCLC patients included 24 smokers and 34 nonsmokers. The
frequency of LOH at one or more loci was rather similar among
smokers (20 out of 24, 83.3%) and nonsmokers (30 out of 33,
90.9%; P¼0.439). The lack of correlation between LOH at one or
more loci and smoking history are divergent to that of previous
results, however, there is no clear explanation for the difference
(Burke et al, 1998).
In agreement with previous studies (Burke et al, 1998; Marchetti
et al, 1998; Tomizawa et al, 1998; Geradts et al, 2000), allelic
deletion of the FHIT locus did not correlate with sex, age, staging,
lymph node metastasis and survival. Thus, our results are
consistent with the role of FHIT abnormalities at a relatively early
stage of pulmonary neoplasia, rather than in the metastatic
progression of invasive lung cancers.
In this study, we did not find a concordance between LOH at the
FHIT locus and loss of Fhit expression in NSCLCs. The
inconsistency between LOH of FHIT locus and Fhit expression
could simply be due to either small deletion or deletion of flanking
marker without affecting the transcriptional regulation of FHIT
gene. Whereas LOH is generally associated with decreased protein
expression, protein inactivation may be due to complex mechan-
isms other than deletion within an allele (Tanaka et al, 1998).
Alternatively, abnormal protein expression may occur in the
absence of genetic alterations through altered splicing fidelity
(Gayther et al, 1997). Besides, methylation of FHIT is another
important mechanism for loss of Fhit expression (Zo ¨chbauer-
Mu ¨ller et al, 2001).
The reported link of FHIT with apoptotic regulation (Ji et al,
1999; Sard et al, 1999) led us to examine its connection to the
status of the p53 protein, a well-characterised antiproliferative
factor, which induces growth arrest and apoptosis in response to
various stimuli (Prives and Hall, 1999). It was previously indicated
that the genetic changes at the FHIT locus may be correlated with
Table 1 Relationships between LOH of FHIT and microsatellite makers and clinicopathologic parameters of patient analysed
LOH
Makers Clinicopathologic parameters No.of cases with LOH(%) No.of cases without LOH (%) P-value
D3S1766 Squamous cell carcinoma 10 (90.9) 1 (9.1) 0.049
Adenocarcinoma 9 (52.9) 8 (47.1)
D3S1766 p53 (+)
a 9 (100) 0 (0) 0.026
p53 ( )
a 10 (52.6) 9 (47.4)
D3S1766 Fhit(+)
a 6 (54.5) 5 (45.5) 0.409
Fhit( )
a 13 (76.5) 4 (23.5)
D3S1289 Male in adenocarcinoma 6 (75) 2 (25) 0.028
Female in adenocarcinoma 4 (23.5) 13 (76.5)
LOH loci X1 Smoker 20 (83.3) 4 (16.7) 0.439
Nonsmoker 30 (90.9) 3 (9.1)
aImmunohistochemical stain, (+): 410%, ( ): o10%; LOH¼ Loss of heterozygosity; FHIT¼ fragile histidine triad.
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sp53 mutations (Burke et al, 1998; Marchetti et al, 1998; Chang et al,
2003), while other investigators found no statistically significant
correlation between FHIT and p53 abnormalities in NSCLCs
(Nelson et al, 1998; Geradts et al, 2000). By examining the FHIT/
p53 profiles, we noticed that the nine cases with synergistic effect
of LOH at FHIT locus and p53 overexpression included six
squamous cell carcinomas and three adenocarcinomas. And 44%
of them were smokers. Since frequent LOH at FHIT locus was
detected in smokers of squamous cell carcinoma with p53
aberrations in Western populations (Garinis et al, 2001), we
speculated that exposure of different carcinogenic agents such as
HPV, cooking fume, etc. in Taiwan (Chen et al, 1990) might have
caused genome instability detected by LOH of FHIT locus in lung
cancer patients of different geographic regions. As described by
Garinis, the main determinant of tumour growth in FHIT LOH
tumours is the state of p53, a finding that strengthens the concept
of p53 protecting the cell from the deleterious effects of tumour
suppressor gene inactivation or oncogene activation (Garinis et al,
2001). Furthermore, the data presented recently constitutes a
further molecular evidence of a field cancerisation effect and
suggest that specific mutations in p53 and FHIT alteration may
occur as an early event of bronchial precancerous lesions (Sozzi
et al, 2002).
In conclusion, this study showed for the first time that FHIT
gene alteration is a very frequent event in both squamous cell
carcinomas and adenocarcinomas of the lung despite whatever the
smoking status. This unexpectedly high incidence may indicate
that specific mechanisms are involved, resulting in frequent
deletions in these loci. It may play a role in carcinogenesis of the
human lung, and may provide some new approaches to early gene
detection for lung cancer. FHIT LOH was not correlated with
important clinical parameters, suggesting that it plays a role early
in the pathogenesis of lung cancer rather than in later metastatic
stages. The particularly frequent FHIT LOH in our NSCLCs and the
absence of correlation with Fhit protein expression implies that the
presence of complex mechanisms of Fhit inactivation. On the other
hand, the significant association between LOH at FHIT and p53
protein overexpression provides evidence of alterations affecting
the two genes. As NSCLC is an aggressive disease and shows an
unfavourable prognosis, a new treatment such as FHIT gene
therapy could represent a desirable breakthrough.
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